Medication, Vaccine, and Folic Acid Use Among Pregnant Women in Belgium: Insights from the <scp>BELpREG</scp> Cohort

BACKGROUND: Safety data for most medications in pregnancy remain limited, yet pharmacological treatment is often necessary. Evidence on real-world medication use in pregnancy including over-the-counter products and folic acid is scarce, especially in Belgium. METHODS: We conducted a drug utilization study using self-reported data from BELpREG, a prospective, web-based pregnancy registry established in November 2022. Pregnant individuals aged ≥ 18 years receiving healthcare in Belgium can enrol voluntarily at any stage in pregnancy and complete online questionnaires at enrolment and every four weeks until delivery. All participants with follow-up beyond the first trimester were included, and trimester-specific cohorts were constructed based on completion of questionnaires after each trimester. Data were extracted in July 2025. RESULTS: This study included 2096 participants, of whom 1767 were followed through trimester 2 and 1136 through trimester 3. Median gestational age at enrolment was 16 weeks. Prevalence estimates of medication use were 80.2% in the six months before conception, 85.8% in trimester 1, 92.0% in trimester 2, and 94.9% in trimester 3. The most common classes were analgesics, vaccines, antihistamines, antianemic preparations, and drugs for acid-related disorders. Paracetamol was most frequently used (35.4% in trimester 1), typically short term (median 3 days), followed by doxylamine-pyridoxine (26.7% in trimester 1). Folic acid supplementation was nearly universal, though only 59.9% met national guideline-concordant criteria. Maternal vaccine uptake was substantial but incomplete, with 66.5% receiving pertussis, 43.7% influenza, and 24.4% COVID-19 vaccination. Exposure to potentially inappropriate or teratogenic medications was rare. CONCLUSIONS: Medication use during pregnancy in Belgium was nearly universal, with high use of paracetamol and doxylamine-pyridoxine. Folic acid and vaccine uptake were substantial, but often not guideline-concordant.

Authors

Institutions

Publication Details

Journal
Pharmacoepidemiology and Drug Safety
Published
2026-04-01
DOI
https://doi.org/10.1002/pds.70369
Primary Topic
Pregnancy and Medication Impact
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Medication, Vaccine, and Folic Acid Use Among Pregnant Women in Belgium: Insights from the BELpREG Cohort

Anne Smits, Michael Ceulemans, Titia Hompes, Jan Y. Verbakel et al.
Pharmacoepidemiology and Drug Safety
Pregnancy and Medication Impact
article

Medication, Vaccine, and Folic Acid Use Among Pregnant Women in Belgium: Insights from the BELpREG Cohort

Anne Smits, Michael Ceulemans, Titia Hompes, Jan Y. Verbakel, Maarten De Vos, Laure Sillis, Veerle Foulon, Sien Lenie, Kristel Van Calsteren, Emily Jacobs, Karel Allegaert
article en

Abstract

BACKGROUND: Safety data for most medications in pregnancy remain limited, yet pharmacological treatment is often necessary. Evidence on real-world medication use in pregnancy including over-the-counter products and folic acid is scarce, especially in Belgium. METHODS: We conducted a drug utilization study using self-reported data from BELpREG, a prospective, web-based pregnancy registry established in November 2022. Pregnant individuals aged ≥ 18 years receiving healthcare in Belgium can enrol voluntarily at any stage in pregnancy and complete online questionnaires at enrolment and every four weeks until delivery. All participants with follow-up beyond the first trimester were included, and trimester-specific cohorts were constructed based on completion of questionnaires after each trimester. Data were extracted in July 2025. RESULTS: This study included 2096 participants, of whom 1767 were followed through trimester 2 and 1136 through trimester 3. Median gestational age at enrolment was 16 weeks. Prevalence estimates of medication use were 80.2% in the six months before conception, 85.8% in trimester 1, 92.0% in trimester 2, and 94.9% in trimester 3. The most common classes were analgesics, vaccines, antihistamines, antianemic preparations, and drugs for acid-related disorders. Paracetamol was most frequently used (35.4% in trimester 1), typically short term (median 3 days), followed by doxylamine-pyridoxine (26.7% in trimester 1). Folic acid supplementation was nearly universal, though only 59.9% met national guideline-concordant criteria. Maternal vaccine uptake was substantial but incomplete, with 66.5% receiving pertussis, 43.7% influenza, and 24.4% COVID-19 vaccination. Exposure to potentially inappropriate or teratogenic medications was rare. CONCLUSIONS: Medication use during pregnancy in Belgium was nearly universal, with high use of paracetamol and doxylamine-pyridoxine. Folic acid and vaccine uptake were substantial, but often not guideline-concordant.

Pharmacoepidemiology and Drug SafetyVol. 35(4)
Research Foundation - Flanders (BE), University of Oxford (GB), University of Plymouth (GB), Erasmus University Rotterdam (NL), KU Leuven (BE)
Good health and well-being
Openalex Percentile: Top 18%
Pregnancy and Medication Impact
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.